1. Scrip
  2. >>Business
  3. >>Deals

Sobi Pays $100m Upfront For Selecta Gout Drug

Set To Challenge Horizon’s Krystexxa

 
• By Kevin Grogan

Swedish Orphan Biovitrum has taken a stake in Selecta and got access to SEL-212, which it is hoping will win a head-to-head trial against Horizon's Krystexxa, the gold standard for chronic refractory gout.

Gout
The refractory gout market is worth $1bn in the US alone • Source: Shutterstock

Swedish Orphan Biovitrum AB (Sobi) has spied an opportunity in the uncontrolled gout market and is paying big bucks to license a therapy from Selecta Biosciences Inc. of the US that could challenge the current standard of care, Horizon Therapeutics PLC's Krystexxa.

The pact centers around SEL-212, a combination therapy comprised of pegadricase, a recombinant enzyme that metabolizes uric acid, and ImmTOR,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business